Back to top
more

Novavax (NVAX)

(Real Time Quote from BATS)

$14.64 USD

14.64
2,719,433

+0.79 (5.70%)

Updated Jul 22, 2024 01:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates

by Zacks Equity Research

Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.

Mark Vickery headshot

Markets Up Big Monday; Zoom (ZM) Beats, Novavax (NVAX) Misses Q4

by Mark Vickery

The Dow rose 1.95% on the day, +603 points; the S&P 500 gained 2.38%; the Nasdaq rose 3%, nearly 400 points; and the small-cap Russell 2000 took the cake, +3.37%.

Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q4

by Zacks Equity Research

Endo's (ENDP) earnings and sales beat estimates in the fourth quarter.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed the most recent trading day at $243.23, moving -0.76% from the previous trading session.

Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

During Novavax's (NVAX) upcoming fourth-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.

Earnings Preview: Novavax (NVAX) Q4 Earnings Expected to Decline

by Zacks Equity Research

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Hedge Fund Diaries: Who Was Buying Your Stocks?

by Kevin Cook

SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.

Tracey Ryniec headshot

Are Stocks Too Hot to Buy?

by Tracey Ryniec

Lots of investors chased the big gains in the WSB/Reddit trades, but those stocks aren't the only ones that are soaring. How do you keep your cool in this red-hot market?

Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA

by Zacks Equity Research

Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA

Kevin Cook headshot

Biotech Bonanza: COVID Launches Science at Warp Speed

by Kevin Cook

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More

by Zacks Equity Research

Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.

Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Novavax (NVAX) closed at $264.41 in the latest trading session, marking a -1.45% move from the prior day.

Sanghamitra Saha headshot

6 ETFs You May Love to Buy for February

by Sanghamitra Saha

February is not known for good stock returns. However, this year could be different as global economies and corporates will strive hard to register a fast rebound from the COVID-19 slump.

Sanghamitra Saha headshot

Top-Performing ETFs of Last Week

by Sanghamitra Saha

Simple profit-booking and some warnings from the too-big-to-fail companies probably led to crash in Wall Street last week.

Sweta Jaiswal, FRM headshot

Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update

by Sweta Jaiswal, FRM

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study

by Zacks Equity Research

Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.

Mark Vickery headshot

Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets

by Mark Vickery

The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.

AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.

Novavax (NVAX) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Novavax (NVAX) closed at $127.43, marking a -1.96% move from the previous day.

Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD

by Zacks Equity Research

The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.

Rimmi Singhi headshot

Make a Fortune With These 4 High Earnings Yield Picks

by Rimmi Singhi

While comparing stocks, if other factors are similar, investors can look out for the one with higher earnings yield. Stocks including GM, WGO, NVAX and MT score high in that parameter.

Ekta Bagri headshot

3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic

by Ekta Bagri

The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.

ERYTECH Pharma (ERYP) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.

Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View

by Zacks Equity Research

Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.